BMS-8

• Description :

  BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1].

• Product Name Alternative :

  CS-3150; XL-550

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  PD-1/PD-L1

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-8.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles :

  CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC=C(C=C3Br)CN4CCCCC4C(O)=O

• Molecular Formula :

  C27H28BrNO3

• Molecular Weight :

  494.42

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Eun-Hye Kim, et al. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions. Int J Mol Sci. 2020 May 21;21 (10) :3639.|[2]Danfeng Shi, et al. Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship. Front Chem. 2019 Nov 12;7:764.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1675201-90-7]